Shareholder to discuss options, including sale of company, with Amylin Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., Nov. 3 - Amylin Pharmaceuticals, Inc. investor Eastbourne Capital Management, LLC said it intends to discuss ways to enhance shareholder value with the company's management, other shareholders and third parties.

According to a schedule 13D/A filed with the Securities and Exchange Commission, possible actions to consider may include an acquisition by a third party.

Eastbourne's standstill agreement with the company automatically terminated on Aug. 27, allowing the investor to have conversations with the San Diego biopharmaceutical company's management, board and other shareholders to discuss ways to maximize product sales and enhance shareholder value, a prior SEC filing said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.